Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.

摘要: OBJECTIVE Discontinuation of dopamine agonist (DA) treatment in women with prolactinoma after menopause is a potential approach; studies systematically assessing long-term outcomes are lacking. Our aim was to investigate the natural history this group. DESIGN/PATIENTS Retrospective cohort study diagnosed before and who were not on DA. RESULTS Thirty included. Twenty-eight received DA (median duration 18 years, median age at withdrawal 52 years). At last assessment follow-up 3 years) compared values 6-12 months stopping DA, Prolactin (PRL) increased 15%, decreased but normalized 33% normal 52%; PRL levels or visible adenoma imaging withdrawal, presence macro-/microadenoma diagnosis predictors normoprolactinaemia review, whereas were. Adenoma regrowth detected 2/27 patients (7%), showed gradual increase PRL. Comparison 28 had their revealed lower risk hyperprolactinaemia recurrence postmenopausal group (HR:0.316, 95% CI: 0.101-0.985, P < .05). Two microprolactinoma perimenopausal period been offered DA; (but normalized) during observation 1 8 years. CONCLUSIONS over time nearly half serum useful predictor. Nonetheless, 7% demonstrated which, given life expectancy postmenopause, necessitate regular monitoring cases persistent hyperprolactinaemia.